A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
Information source: Duke University
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Herpes Simplex Virus; Neonatal Sepsis
Intervention: Acyclovir (Drug)
Phase: Phase 1
Sponsored by: Duke University
Official(s) and/or principal investigator(s):
Phillip B Smith, M.D., Principal Investigator, Affiliation: Duke University
Phillip B Smith, M.D., Phone: 919-668-8951, Email: email@example.com
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies.
Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been
adequately studied in full-term or premature neonates. HSV is a very serious infection in
babies <6 months of age and often results in death or profound mental retardation. HSV
leads to profound mental retardation in young infants because the virus attacks the central
The investigators hypothesize that the currently recommended dose of acyclovir is inadequate
to produce adequate blood levels to combat herpes simplex infection. The investigators
propose to study acyclovir levels in the blood of babies who are placed on acyclovir to
treat a suspected HSV infection. This will allow them to determine the appropriate dose in
premature infants. This is an unmet public health need because it is likely that the drug
behaves differently in premature infants than it does in term infants and older children.
Premature babies have more body water and less body tissue. Their kidneys are more immature
and do not function as well as full term infants. Premature neonates are also at the
greatest risk from herpes infection because they have poorly functioning immature immune
systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in
Official title: An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary outcome is the PK and safety of acyclovir in premature infants <45 postnatal days. It is expected that > 90% of infants will have Cmin > 3 mg/L.
Neonatal herpes infection carries a major risk of death if untreated. Prognosis is related
to disease extent and timing of therapy, making early diagnosis crucial. Mortality in the
pre-antiviral era was 90% for disseminated disease and 50% for central nervous system (CNS)
disease. Institution of high-dose (60 mg/kg/day) antiviral therapy with acyclovir has
reduced mortality to 31% for disseminated disease and 6% for CNS disease. 1 Although
acyclovir has reduced mortality dramatically, morbidity remains high.
Study population: Infants < 45 days postnatal age, suspected to have a systemic infection
divided into groups by gestational and postnatal age:
Group-1: 23-29 weeks gestational age, <14 days postnatal age Group-2: 23-29 weeks
gestational age, 14-44 days postnatal age Group-3: 30-34 weeks gestational age, <45 days
Intravenous acyclovir will be administered for 3 days.
Timing of PK sample collection will be with respect to the end of each IV infusion. Timed PK
sampling will be drawn at doses 1, and doses 5, 6, 7, 8, or 9.
0-15 minutes after completion of the 1st dose; Within 30 minutes prior to administration of
Steady state [doses 5 or 6 (groups 1 and 2), doses 8 or 9 (group 3)]:
Within 30 minutes prior to dose; 0-15 minutes after completion of the dose; 2-3 hours after
completion of the dose; Within 30 minutes prior to administration of the next dose
6-7 hours after the last dose (groups 1 and 2)and 10-11 hours after the last dose (group 3)
Minimum age: N/A.
Maximum age: 45 Days.
The investigator or other study site personnel will document in the source documents
(e. g., the hospital chart) that informed consent was obtained. Laboratory tests or
non-pharmacologic treatment procedures that were performed as standard of care within 72
hours prior to first dose of study drug may be used for screening procedures and recorded
in the CRF.
1. < 45 days of age at the time of initial study drug administration.
2. Sufficient venous access to permit administration of study medication.
3. Availability and willingness of the parent/legal guardian to provide written informed
4. Suspected HSV sepsis OR At least two (2) of the following
- Signs of sepsis AND negative blood cultures for >24 hours7
- Respiratory distress8
- Fever ≥ 38. 0°C7
- Skin lesions7,8
- Seizures (clinical OR EEG confirmed)7
- AST OR ALT >2 X upper limit of normal7,8
- >20 WBCs/µL or >500 RBCs/µL7
1. History of anaphylaxis attributed to acyclovir.
2. Serum creatinine >1. 7 mg/dL.
3. Urine output <0. 5 mL/kg/hour over the previous 12 hours
4. Previous participation in the study.
5. Concomitant condition, which in the opinion of the investigator would preclude a
participant's participation in the study
Locations and Contacts
Phillip B Smith, M.D., Phone: 919-668-8951, Email: firstname.lastname@example.org
Wesely Medical Center, Wichita, Kansas 67214-4976, United States; Recruiting
Paula Delmore, MSN, Phone: 316-962-8555, Email: email@example.com
Paula Delmore, MSN, Principal Investigator
Tulane School of Medicine, New Orleans, Louisiana 70112, United States; Not yet recruiting
Jane Reynolds, MD, Phone: 504-988-5315, Email: firstname.lastname@example.org
Euming Chong, MD, Principal Investigator
Duke University, Durham, North Carolina 27713, United States; Recruiting
Robert W Lenfestey, M.D., Phone: 919-684-9298, Email: email@example.com
Kim Fisher, PhD., Phone: 919-681-4913, Email: firstname.lastname@example.org
Robert W Lenfestey, M.D., Principal Investigator
Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis. 2002 Jan;13(1):6-11. Review.
Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong SJ, Kiell J, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001 Aug;108(2):230-8.
Lietman PS. Acyclovir clinical pharmacology. An overview. Am J Med. 1982 Jul 20;73(1A):193-6. Review.
Englund JA, Fletcher CV, Balfour HH Jr. Acyclovir therapy in neonates. J Pediatr. 1991 Jul;119(1 ( Pt 1)):129-35.
Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 Jul 20;73(1A):186-92. Review.
Hintz M, Connor JD, Spector SA, Blum MR, Keeney RE, Yeager AS. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am J Med. 1982 Jul 20;73(1A):210-4.
Yeager AS. Use of acyclovir in premature and term neonates. Am J Med. 1982 Jul 20;73(1A):205-9.
Kimberlin DW. When should you initiate acyclovir therapy in a neonate? J Pediatr. 2008 Aug;153(2):155-6. No abstract available.
Brigden D, Bye A, Fowle AS, Rogers H. Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother. 1981 Apr;7(4):399-404. No abstract available.
Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis. 1988 Feb;157(2):385-8. No abstract available.
Starting date: September 2011
Last updated: September 19, 2011